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Abstract
Background A major obstacle to achieving effective DNA-based therapeutics
is efficient delivery of the DNA to its site of action in the cell. Upon
internalization by endocytosis, the endosomal membrane represents a
critical physical barrier preventing access of DNA to the cell cytosol. In
order to overcome the membrane barrier and facilitate cytosolic entry, the
endosomolytic bacterial protein listeriolysin O (LLO) is a potentially promising
agent.
Methods LLO was incorporated in an anionic liposome-entrapped
polycation-condensed DNA delivery system (LPDII). Plasmid DNA was con-
densed using protamine sulfate and then complexed to anionic liposomes. LLO
was incorporated into the delivery vehicle through encapsulation in anionic,
pH-sensitive liposomes. Transfection levels were monitored using a model
reporter plasmid encoding luciferase in P388D1 cells, a macrophage-like cell
line.
Results Transfection using the anionic LPDII delivery platform was
enhanced through incorporation of LLO. Additionally, the net charge of
the condensate, the lipid composition, and the total amount of LLO-
liposomes were all capable of modulating the transfection levels of the
vehicle. Importantly, in the presence of serum, transfection levels using the
LLO-containing LPDII system were comparable to established cationic lipid
delivery systems.
Conclusions LLO is capable of facilitating transfection using an anionic
LPDII system. This anionic delivery vehicle represents the successful
combination of the LPDII system for condensation of the DNA with the
unique endosomolytic properties of LLO for improved transfection using
plasmid DNA. Copyright  2005 John Wiley & Sons, Ltd.
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Introduction
With the expansion of information arising from advances in genomics, new
applications for gene therapy are being conceptualized increasingly rapidly.
The field of gene delivery must continually strive to develop necessary
technologies meeting the specific needs for the array of gene therapy pro-
tocols. While some gene delivery technologies, including both viral and
non-viral vectors such as cationic liposomes and polymer-based deliv-
ery systems, have already shown great promise, each system has unique
limitations [1–5]. Therefore, promising delivery concepts that build on
Copyright  2005 John Wiley & Sons, Ltd.
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existing, successful technologies must continue to be
developed and refined.
Physical barriers to the cytosolic and nuclear delivery
of genes represent key obstacles to the success of gene
therapy. DNA delivery encompasses multiple steps in
series: delivery to the specific tissue or cell target,
passage across the cell membrane to gain cytosolic access,
and transport into the nucleus [4,6]. Many innovative
approaches are being taken to overcome each barrier in
this multistep process of delivery. Often these individual
solutions are in some respects modular; development
of a specific functionality to overcome one barrier
can be used in combination with those developed for
preceding or subsequent barriers. For example, various
membrane-disrupting components incorporated in both
targeted polyplex and lipoplex gene delivery systems
can significantly increase transfection levels beyond each
system alone [7]. Thus, the focused development of
technologies aimed at specific barriers, when used in
combination, can lead to overall progress of successful
DNA delivery technologies.
Delivery across the plasma membrane and into the
cytosol of cells is one critical barrier to effective gene
delivery [8,9]. The large size and anionic nature of plas-
mid DNA (pDNA) make it membrane-impermeant. Thus,
naked pDNA is typically degraded extracellularly or taken
up by cells and degraded in the endolysosomal com-
partment without ever reaching the cytosol. In the study
reported in this paper, we investigated the combination of
two promising technologies: anionic LPDII particles and
listeriolysin O (LLO)-mediated cytosolic delivery. LPDII,
a liposome-entrapped polycation-condensed pDNA deliv-
ery vehicle, utilizes anionic liposomes to envelop pDNA
that has been condensed using polycations [10]. In the
LPDII delivery system model of self-assembly, pDNA is
first condensed with a polycation and this condensate
is then electrostatically complexed, or entrapped, within
liposomes [10]. While LPDII provides a platform upon
which to build, the relatively low transfection efficiency
of the anionic LPDII particle calls for further modifica-
tions, such as the addition of a targeting moiety or an
endosomolytic agent.
To expand the utility and improve the efficiency of
the LPDII particle, we have explored the incorporation
of an additional functionality, an endosomolytic pore-
forming protein from the facultative intracellular bacteria,
Listeria monocytogenes, listeriolysin O (LLO), to form
an LLO-LPDII complex, and investigated its effect on
pDNA delivery. To this end, LLO was encapsulated inside
the anionic liposomes of LPDII for co-transport with the
condensed pDNA complex. LLO has been demonstrated
to be capable of breaching the endosomal membrane,
allowing escape of endosomal or phagosomal contents
into the cytosol of cells [11]. Furthermore, the activity
of LLO is elevated and optimal at pH 5–6 of endosomes,
making it ideal for applications where endosomal release
is required [9,12].
The versatility of LLO as a component in a delivery
system is clear. LLO has been engineered to deliver
intact bacteria to the cytosol of a cell; genetically mod-
ified Bacillus subtilis which express LLO are capable
of endosomal escape, thus LLO is sufficient to impart
endosomolytic function [13]. Utilizing purified or recom-
binant LLO, enhanced macromolecular delivery has been
demonstrated with dyes and model proteins using the
LLO-mediated escape mechanism [11], and recent work
has shown that LLO-containing liposomes encapsulating
a model protein are capable of enhancing the CD8+ cyto-
toxic T lymphocyte-based immune response in immunized
mice [14]. LLO is also capable of delivering antisense
oligonucleotides that are co-encapsulated in liposomes
for down-regulation of cell-surface proteins [15].
This study is the first exploration of a liposome-
based, LLO-mediated delivery system for pDNA. We
hypothesized that addition of LLO in the LPDII system
would improve transfection efficiency by improving access
of the pDNA to the cytosol. LPDII and LLO-LPDII particles
were formed using a model pDNA encoding luciferase
under the cytomegalovirus (CMV) promoter. In keeping
with the flexibility afforded by the original LPDII particle,
modifications to the original LPDII system also include
the use of protamine sulfate as the condensing polycation
rather than poly(L-lysine). Protamine sulfate has several
advantages as a condensing agent, including its current
use in clinical treatments, which has provided extensive
data to suggest that protamine is nontoxic, biocompatible,
and weakly immunogenic [16]. Anionic pH-sensitive
liposomes serve as the exterior of the complex such
that endosomal uptake will trigger destabilization of
the liposome and release of the encapsulated LLO [17].
We demonstrate that the LPDII particle can be greatly




Protamine sulfate (grade III, Clupeine) and cholesteryl-
hemisuccinate (CHEMS) were purchased from Sigma. Egg
phosphatidylethanolamine (PE), egg phosphatidylcholine
(PC), 1,2-dioleoyloxy-3-trimethylammonium propane
(DOTAP), and dioleoylphosphatidylethanolamine (DOPE)
were purchased from Avanti Polar Lipids, Inc. (Alabaster,
AL, USA). Lipofectamine was purchased from Invitrogen
(Carlsbad, CA, USA).
Preparation of plasmid containing the
luciferase gene
Plasmid DNA was obtained from the plasmid pNGVL3
encoding firefly luciferase under the cytomegalovirus
(CMV) promoter (a gift from Dr. Gary Nabel, Vaccine
Research Center, National Institutes of Health, MD, USA).
Plasmid DNA was harvested and purified from E. coli
using the Qiagen Plasmid maxi kit (Qiagen, CA, USA).
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The purity and concentration of pDNA was determined
spectrophotometrically using the absorbances at 280 and
260 nm.
LLO purification
Recombinant LLO was produced from E. coli BL21(DE3)
which had been transformed with pET29b containing
the LLO gene, hly, modified to include a six-histidine
tag (a gift from Dr. Daniel Portnoy, University of
California, Berkeley, CA, USA) [18]. The LLO was purified
using a Ni-NTA column (Qiagen). A 500 ml culture
generally produced ∼10 mg of protein. LLO purity was
analyzed by sodium dodecyl sulfate/polyacrylamide gel
electrophoresis (SDS-PAGE) and Coomassie blue staining.
Protein concentration was determined by BCA assay
(Pierce, IL, USA) using a standard of bovine serum
albumin (BSA). The activity of LLO was determined
using an in vitro sheep red blood cells (RBCs) hemolysis
assay as previously described [14]. Briefly, sheep RBCs
(ICN Biomedicals, OH, USA) were suspended in HEPES-
buffered saline (10 mM HEPES, 140 mM NaCl, pH 7.4)
at 108 cells/ml. Known amounts of purified recombinant
LLO were added to 2 ml of suspended RBCs, and changes
in the right-angle light scattering of RBCs undergoing lysis
were monitored using a fluorometer (Jobin Yvon-Spex
Instruments SA., NJ, USA). The excitation and emission
monochromators were set to 590 nm.
Cell culture
The murine macrophage P388D1 cell line was purchased
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). Cells were cultured in RPMI-1640
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml
streptomycin, 10 mM HEPES, and 1 mM sodium pyruvate
(complete RPMI). Cells were grown at 37 ◦C in a 5% CO2
humidified atmosphere.
Protamine-pDNA complex formation
Protamine-pDNA complexes at theoretical charge ratios
from 0.64/1 to 2.2/1 (+/−) were prepared by adding
6 µg of pDNA in 100 µl HEPES-buffered glucose (HBgluc,
10 mM HEPES, 280 mM glucose, pH 8.5) to varying
amounts of protamine in 200 µl HBgluc while rapidly
vortexing. The pDNA was added to the excess protamine
(excess is based on charge ratios) unless a negative overall
charge ratio was desired. Theoretical charge ratios are
calculated based on: 1 µg DNA is equivalent to 3.1 nmol
negative charge, and 1 nmol protamine sulfate contains 21
nmol positive charge. The charge on the protamine-DNA
condensate was monitored by dynamic light scattering
in a zeta-potential/particle sizer instrument (NICOMP
380ZLS). As previously shown, pDNA condensed with
increasing amounts of protamine displayed a neutral
zeta-potential at a theoretical charge ratio of 1.25
amino groups in protamine to phosphates of pDNA
[19]. Thus, all protamine-DNA condensates are reported
here using theoretical charge ratios, with condensates
formed at a theoretical charge ratio higher than 1.25/1
(+/−) exhibiting a positive zeta-potential. Particle size of
protamine-DNA condensates was also monitored using the
NICOMP 380ZLS equipped with an Avalanche photodiode
detector. Representative mean diameter for condensates
formed at 1.6/1 (+/−) was 100.6 ± 15.5 nm. In
agreement with previous work, condensates formed
closer to the charge neutral point tended to aggregate
(175 ± 21.7 nm) [10,19]. Condensates with a net positive
charge were able to occlude ethidium bromide (EtBr) in
agarose gel analysis (data not shown). Briefly, pDNA
was mixed with protamine sulfate at varying ratios as
described above. A 0.8% agarose gel was prepared (0.4 g
agarose in 50 ml ddH2O) and 5 µl of EtBr were added to
the solution. After the samples had been loaded, the
gel was run at 100 V for 15 min. The gel was then
immediately analyzed under UV light using a Kodak
digital camera and Metamorph Image analysis software.
A polyacrylamide gel (20%) was run in parallel with the
same samples loaded in order to confirm, through protein
staining using Coomassie blue, the presence of samples
which did not display UV fluorescence in the agarose gel
due to EtBr occlusion. Lack of fluorescence of EtBr in
the presence of pDNA reflects an inability of the EtBr to
intercalate into the pDNA due to condensation.
Liposome preparation
Liposomes were prepared using thin film hydration
and the freeze/thaw technique. Briefly, lipids dissolved
in chloroform were added at a 2 : 1 mole ratio of
either PE/CHEMS or PC/CHEMS, and dried in a
rotary evaporator under a stream of argon to a thin
film. The lipid film was hydrated using 1 ml of 3-
fold diluted HBgluc (hypotonic HBgluc), either with or
without 200 µg LLO, and vortexed. The liposomes were
subjected to five freeze/thaw cycles in an ethanol bath
at −80 ◦C and sonicated twice for 30 s in a bath-type
sonicator (Laboratory Supplies Company, NY, USA) [20].
Liposomes were then passed through a Sepharose CL-
4B gel filtration column (Amersham Pharmacia Biotech)
equilibrated with HBgluc to remove unencapsulated LLO.
Encapsulation efficiency of LLO was generally 15–25% in
both PE/CHEMS and PC/CHEMS formulations. Typical
diameter of PE/CHEMS liposomes by dynamic light
scattering was 186.4 ± 40.5 nm. Addition of LLO did
not affect liposome size. The charge contribution from
liposomes for complex formation was calculated using
the concentration of CHEMS in the liposome preparation.
CHEMS concentration was derived from experimental
determination of phosphate content in the liposome
preparation following gel filtration and the molar
ratio of phospholipids and CHEMS (PE/CHEMS or
PC/CHEMS, 2 : 1).
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Formation of LPDII and LLO-LPDII
complexes
LPDII and LLO-LPDII complexes were formed based on
methods previously developed for LPDII [10]. Protamine-
pDNA condensates at a concentration of 20 µg pDNA/ml
in 300 µl were added to an equal volume of liposomes,
either blank or LLO-containing, to form LPDII or LLO-
LPDII particles, respectively. The complexes were then
diluted into an equal volume of complete RPMI-1640
containing 10% FBS for transfection. Typical diameter
of the LLO-LPDII complex by dynamic light scattering
was 212.4 ± 46.9 nm. Zeta-potential analysis of the
protamine-pDNA condensate alone at a 1.6 : 1 positive-to-
negative charge ratio was 7.08 ± 0.57 mV. Zeta-potential
measurements were −11.9 ± 4.3 mV following addition
of anionic liposomes to a net theoretical charge of
−1.9 nmol/µg pDNA.
Transfections
P388D1 cells were plated at a density of 1.5 × 105 cells
per well in 24-well plates and cultured for 16–24 h prior
to transfection. Cells were typically ∼70% confluent at
the time of the experiment. In all transfection assays,
200 µl/well of the transfection sample containing 2 µg
pDNA in 5% serum-containing RPMI1640 were added
dropwise and incubated with the cells for 4 h. The
transfection media was removed after 4 h and the cells
were washed once and replaced with fresh serum-
containing RPMI complete media. Cells were assayed
for gene expression after 72 h. Assays were performed in
triplicate.
Other transfection agents
A comparative study of transfection using several
commonly used transfection agents was undertaken.
Chloroquine, DOTAP/DOPE (1 : 1), or Lipofectamine was
added to transfection mixtures containing 2 µg DNA. For
Lipofectamine, samples were prepared with 2 µg pDNA
and added to the cells according to the manufacturer’s
instructions (Invitrogen). DOTAP and DOPE were mixed
at a 1 : 1 ratio and mixed with 2 µg pDNA. In chloroquine-
mediated samples, pDNA was condensed according to the
above procedure with protamine, and 80 µM chloroquine
was added directly to the transfection mixture. All samples
were incubated for 4 h, after which the samples were
removed and replaced with fresh serum-containing media,
and incubated for 72 h. All samples were then assayed as
described.
Luciferase assay
Transfection was measured by detecting luciferase
production using a luciferase assay kit (Promega,
WI, USA). Briefly, the cells were lysed using 100 µl
Reporter lysis buffer (Promega) and subjected to one
freeze/thaw cycle. The cell lysates were then collected
and centrifuged at 14 000 rpm for 90 s. Then, 20 µl of the
supernatant were assayed for luminescence with 100 µl
luciferase substrate (Promega) using an AutoLumat LB953
luminometer (EG&G Berthold) for 10 s. Readings were
normalized for total cellular protein concentration in the
extracted samples using a BCA assay (Pierce). BCA assays
were performed following the manufacturer’s protocol
using a standard of BSA. Cellular protein recovery is
reported as the protein recovery, as determined by BCA,
of each sample as a percentage of the cellular protein
recovery by BCA of a control sample that was not
transfected with any DNA but which was otherwise treated
identically to test samples.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism version 4.0 (GraphPad Software, San Diego, CA,
USA). One-way analysis of variance (ANOVA) with
Tukey’s post-test was performed on all data sets unless
otherwise indicated. Studies analyzed with two-way
ANOVA used the Bonferroni post-test.
Results
Transfection using LLO-LPDII particles
To investigate whether addition of LLO to the LPDII sys-
tem augments transfection, P388D1 cells were transfected
with either cationic protamine-DNA (P-D) condensate,
anionic LPDII particles, or anionic LLO-LPDII complexes
(Figure 1). P388D1 cells, a macrophage-like cell line,
represent an appropriate in vitro cell model as liposo-
mal carriers are naturally cleared from the circulation
in vivo by macrophages of the reticuloendothelial system
[21,22]. The protamine-DNA condensates were com-
plexed to anionic liposomes to a net negative charge.
In order to investigate the effect of LLO activity, the LLO-
containing liposomes were heated at 75 ◦C for 10 min
prior to complex formation and compared as a control
formulation; incubation at 75 ◦C for 10 min is sufficient
to abolish LLO activity as monitored by a hemolysis assay
(data not shown). Additionally, the protamine-DNA con-
densate was complexed with blank anionic liposomes in
the presence of free LLO and this LPDII with free LLO mix-
ture was used to transfect cells. The data in Figure 1 show
that incorporation of LLO in the LPDII complex improved
transfection levels more than 30-fold over both LPDII
without LLO and cationic protamine-condensed pDNA
(p < 0.001). This enhancement of transfection upon the
incorporation of LLO in LPDII was abrogated and reduced
to the levels of protamine-DNA alone in the samples in
which LLO-containing liposomes were heat-inactivated
(p < 0.001). Furthermore, addition of free LLO to wells
Copyright  2005 John Wiley & Sons, Ltd. J Gene Med 2005; 7: 1077–1085.
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Figure 1. Effect of encapsulation of LLO in LPDII particles. pDNA
was condensed with protamine at a 1.6 : 1 (+/−) theoretical
charge ratio and administered either alone (P-D) or further
complexed with PE/CHEMS liposomes. Complexes contained
either blank liposomes (LPDII) or liposomes containing LLO
(LLO-LPDII). Complexes were administered to P388D1 cells in
transfection media containing 5% FBS. As a control, LLO-LPDII
complexes were formed using liposomes with LLO which had
been heat-inactivated for 10 min at 75 ◦C (LLO-LPDII (HI)). Also,
LPDII were formed in the presence of 200 µg in the 200 µl
transfection mixture (LPDII + free LLO). On the secondary
axis, luciferase assay results were converted to luciferase
concentration using a standard curve of known concentrations
of luciferase enzyme. Results are reported as the mean ± SEM of
five experiments performed in triplicate. ∗p < 0.001
transfected with LPDII did not significantly increase trans-
fection over LPDII alone.
Effects of protamine/pDNA ratio on
LLO-LPDII transfection levels
The effect of altering the protamine-to-pDNA ratio in
the LLO-LPDII was determined by changing the amount
of protamine while holding the amount of pDNA
constant, thereby producing protamine-DNA condensates
of varying net charge (Figure 2). Both anionic and cationic
condensates were studied, with theoretical charge ratios
of 0.64/1 and 0.96/1 (+/−) forming negatively charged
condensates and ratios of 1.28/1, 1.6/1, 1.92/1, and
2.24/1 (+/−) forming positive condensates as verified by
zeta-potential analysis (data not shown). All condensates
were then mixed with LLO-containing anionic liposomes
such that the theoretical net charge on the complexes
was equivalent to 1.9 nmol negative charge/µg DNA.
Anionic protamine-DNA condensates (those with (+/−)
ratios of 0.64/1 and 0.94/1) mixed with LLO-liposomes
showed minimal transfection efficiency; transfection
was comparable to protamine-DNA alone. All cationic
protamine-DNA condensates (those with +/− ratios of
1.28/1 to 2.24/1) which had been complexed to anionic
liposomes showed 10- to 100-fold higher transfection
levels than the anionic condensates (p < 0.05 for all
anionic vs. cationic condensates). Similarly, all cationic
condensates showed significantly higher transfection than
pDNA condensed with protamine at a 1.6/1 (+/−) charge
ratio in the absence of LLO-liposomes (p < 0.05). Samples
within each net charge grouping showed no significant
differences.
The effect of LLO-liposome/non-LLO-
liposome (blank liposome) ratio
The effect of the LLO content in the LLO-LPDII was
examined by fixing the protamine, pDNA, and lipid
content with the condensate charge ratio at 1.6/1
(+/−) and total lipid content at 1.9 nmol negative
charge/µg pDNA. Prior to addition to the protamine-
DNA condensate, liposomes were pre-mixed to specified
ratios of blank to LLO-containing PE/CHEMS liposomes
keeping the total amount of lipid fixed.
The data showed that as the percentage of LLO-
containing liposomes was decreased, the transfection
level also decreased (Figure 3). The data showed an
increase in gene expression with increasing incorporation
of LLO-liposomes (p < 0.001 by one-way ANOVA with
linear trend post-test). Inclusion of 50% LLO-liposomes or
higher was sufficient to significantly improve transfection
over protamine-DNA and LPDII (equivalent to 0% LLO-
liposomes; p < 0.05).
The effect of LLO-liposome/
protamine-DNA condensate ratio
The next variable investigated while holding the amounts
of protamine and pDNA constant was the total amount
Figure 2. Effect of protamine-pDNA ratio in LLO-LPDII com-
plexes on transfection activity. pDNA was condensed using
various amounts of protamine sulfate to specific charge ratios
based on the theoretical ratio of positively charged protamine
to negatively charged DNA. The condensates were then com-
plexed with anionic PE/CHEMS liposomes containing LLO to a
net theoretical charge of −1.9 nmol/µg pDNA. Protamine-pDNA
condensate at a 1.6 : 1 (+/−) charge ratio was administered in
the absence of liposomes as a control (P-D). Results are reported
as the mean ± SEM of three experiments performed in triplicate.
∗p < 0.05
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Figure 3. Dependence of transfection activity on LLO content.
Protamine-pDNA was condensed at a 1.6 : 1 (+/−) charge
ratio and complexed to PE/CHEMS liposomes to a net
−1.9 nmol charge/µg pDNA. The total amount of liposomes
was kept constant as the percentage of those liposomes which
encapsulated LLO was increased from all blank liposomes
(0%) to all LLO-containing liposomes (100%). Complexes were
administered in transfection media containing 5% FBS. Results
are reported as the mean ± SEM of three experiments performed
in triplicate. p < 0.001 by one-way ANOVA with linear trend
post-test
of LLO-containing liposomes in the LLO-LPDII system.
We hypothesized that increasing the total amount of
LLO-containing liposomes per protamine-DNA condensate
would increase transfection efficiency. Formulations were
composed of protamine-DNA at a 1.6/1 (+/−) charge
ratio complexed to increasing amounts of LLO-containing
liposomes (Figure 4). The lowest amount of liposomes
used in Figure 4 corresponds to the theoretical isoelectric
point of the complexes. As the amount of LLO-containing
liposomes added was increased, however, the transfection
efficiency was diminished. Addition of 10-fold more lipid
reduced the transfection levels to those of protamine-DNA
alone. Presence of excess LLO-liposomes also resulted in
diminished recovery of total cellular protein, as monitored
by BCA assay (Figure 4).
Effect of pH-sensitivity of the liposomes
LLO delivered in the LLO-LPDII complex is retained
with the complex through encapsulation inside the
enveloping liposomes. We hypothesized that the ability
of LLO to facilitate endosomal release of pDNA is
dependent on release of the LLO molecules from
the liposomal encapsulation once the complex reaches
the endosomes. To study this we used PC/CHEMS
liposomes, a pH-insensitive formulation, in contrast to pH-
sensitive PE/CHEMS liposomes [11,23–25]. Protamine-
DNA condensate at a 1.6/1 (+/−) theoretical charge ratio
Figure 4. Effect of the total liposome content on transfection
activity. pDNA was condensed using protamine to a 1.6 : 1
(+/−) theoretical charge ratio. The cationic protamine-pDNA
condensates were complexed with increasing amounts of
anionic PE/CHEMS liposomes containing LLO past the charge
neutralization point to include increasing excess net negative
charge. pDNA condensed with protamine in the absence of
liposomes was given as a control formulation (P-D). Results are
reported as the mean ± SEM of three experiments performed in
triplicate
was complexed with a fixed amount of excess anionic
liposomes made of either PC/CHEMS or PE/CHEMS. To
assess the relative effectiveness of LLO in each of the two
systems, the two lipid compositions were each tested with
LLO-liposomes at three ratios of blank liposomes to LLO-
liposomes: entirely blank liposomes (0% LLO-liposomes),
liposomes pre-mixed to include 50% LLO-liposomes and
50% blank liposomes (50%), and entirely LLO-containing
liposomes (100%). As shown in Figure 5, LLO was less
effective at improving transfection in the pH-insensitive
system (p < 0.05 for PC vs. PE). While a modest increase
in transfection was observed in the PC/CHEMS system
upon LLO incorporation, the effect was more pronounced
in the PE/CHEMS formulation, with p < 0.05 for both
50% and 100% LLO-liposome formulations compared to
formulations lacking LLO (two-way ANOVA).
Effect of serum on transfection
An important attribute of anionic liposomal delivery
systems, in contrast to cationic liposomes or particulate
carriers, is the potential ability to function in the presence
of serum. In order to determine whether the LLO-LPDII
delivery vehicle is affected by the presence of serum, we
used serum-free transfection media for a comparative
study. This study showed no significant difference
between the presence and absence of serum during the
4-h incubation period using either protamine-DNA alone,
anionic LPDII, or LLO-LPDII complexes (Figure 6). LLO
was capable of mediating improved transfection in LLO-
LPDII over LPDII in the presence and absence of serum
(p < 0.05).
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Figure 5. Effect of the pH-sensitivity of liposomes in LLO-LPDII
on transfection activity. Protamine-pDNA condensates at a 1.6 : 1
(+/−) theoretical charge ratio were complexed with anionic
liposomes composed of either pH-insensitive (PC/CHEMS) or
pH-sensitive (PE/CHEMS) lipids to a net charge of −1.9 nmol/µg
pDNA. The portion of each liposome formulation which was
composed of LLO-containing liposomes was varied from all blank
liposomes (0%) to all LLO-containing liposomes (100%). Results
are reported as the mean ± SEM of five experiments performed
in triplicate
Comparison with existing pDNA
delivery methods
The LPDII-LLO delivery system was compared to existing
pDNA delivery technologies in order to assess the relative
efficacy of this system both in the presence and absence of
serum in the transfection medium (Figure 7). Chloroquine
was added to the transfection media (80 µM) during the
4-h transfection period in samples containing protamine-
DNA alone. Additionally, the well-known cationic lipoplex
transfection agents Lipofectamine and DOTAP/DOPE
(1 : 1), formulated with the same amount of pDNA, were
compared to the LPDII-LLO system. In the absence of
serum, the LPDII-LLO system was less effective than
DOTAP/DOPE, Lipofectamine, and chloroquine-mediated
transfection. However, in the presence of 5% serum, the
LPDII-LLO complex showed transfection efficiency as high
as all other transfection-enhancing agents tested.
Discussion
The anionic LPDII delivery system for DNA has previously
been shown to have transfection efficacy when combined
with targeting modalities; therefore, we hypothesized that
Figure 6. The effect of 5% FBS on transfection levels. pDNA
was condensed with protamine sulfate at a 1.6 : 1 (+/−) charge
ratio. The condensate was then complexed with either blank
(LPDII) or LLO-containing PE/CHEMS liposomes (LLO-LPDII)
at a −1.9 nmol net charge/µg pDNA. The complexes were
diluted with serum-containing transfection media as usual,
or with transfection media which did not contain FBS. The
final concentration of FBS in the serum-containing transfection
media was 5%. Results are reported as the mean ± SEM of three
experiments performed in triplicate
Figure 7. Comparison with common transfection agents. pDNA
was condensed with protamine at a 1.6 : 1 (+/−) charge ratio
for the protamine-pDNA, chloroquine (CQ), and LPDII-LLO
samples, and lipid added to the appropriate samples to a net
negative charge of 1.9 nmol/µg pDNA. pDNA was complexed
directly to DOTAP/DOPE (1 : 1) liposomes and Lipofectamine
for DOTAP/DOPE and Lipofectamine samples. pDNA (2 µg)
was transfected per well under all conditions. Chloroquine was
included in the indicated sample in the transfection media at
80 µM during the 4-h transfection period. Results are reported
as the mean ± SEM of three experiments performed in triplicate
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the LPDII particle has the necessary versatility to provide
a general scaffold onto which additional, improved
functionalities can be added for pDNA delivery [10].
This study focuses on combining endosomolytic activity
with the LPDII carrier through the encapsulation of LLO
into the liposomal component of the system. We have
incorporated LLO in the LPDII particles, characterized
key parameters including the ratios of cation to pDNA,
liposomes to pDNA condensate, and LLO to non-LLO-
liposomes, and demonstrated the effect of LLO on
enhanced delivery of pDNA. The results in Figure 1
clearly show that incorporation of LLO into the LPDII
system mediates higher transfection efficiency in P388D1
cells, demonstrating that LLO enables transfection of
macrophages using untargeted anionic LPDII carriers.
The result also shows that inactivation of the LLO prior
to complex formation with pDNA-protamine condensate
results in loss of this transfection enhancement, with
transfection levels falling back to the levels of the LPDII
system without LLO and to those of pDNA condensed
with protamine alone. Thus improved transfection can
be directly linked to the LLO that is active. Our data
is in agreement with previous work in which anionic
LPDII without targeting was not efficient in transfection
and only effective when modified with targeting ligand
[10]. Furthermore, addition of free LLO to transfection
mixtures during formation of LPDII was unable to enhance
transfection above the levels of LPDII alone. This control
mimics the possible condition where LLO is released
from the liposome during LLO-LPDII formation. This
result demonstrates that transfection using LLO-LPDII
requires encapsulation of the LLO with the delivery
vehicle, suggesting that LLO encapsulated in liposomes
is not released during complexation with the cationic
protamine-pDNA during the formation of LLO-LPDII.
The net charge of the protamine-DNA condensate had
a significant effect on transfection levels achieved by
the LLO-LPDII, as seen in Figure 2, with the formation
of a cationic protamine-DNA condensate being essential
for LLO-LPDII effectiveness. The simplest explanation for
this effect is that anionic protamine-DNA condensates
do not form stable electrostatic complexes with anionic
liposomes. The transfection level of the most anionic
condensate (0.64/1, +/−) was comparable to transfection
with protamine-DNA in the absence of liposomes, further
suggesting a lack of complex formation in the anionic
condensates. The anionic condensate data points serve as
both a negative control and as evidence that complexation
through electrostatics is necessary.
After examining the positive trend exhibited by the
inclusion of LLO-containing liposomes, we determined
the effect of increasing the total amount of lipid while
holding both the protamine and pDNA levels constant.
However, we found an acute decrease in transfection with
the presence of excess LLO-containing liposomes. One
explanation for this trend is that the excess liposomes
which do not complex to the protamine-DNA simply
compete with the LLO-LPDII complexes and reduce either
the binding or uptake of the complexes. The data in
Figure 4 indicate that the LLO-LPDII complex is relatively
sensitive to the total liposome content in vitro. This trend
might not be important in vivo, where excess liposomes
would be unlikely to exert a significant competitive
effect at a specific cell target. Additionally, some toxicity
was demonstrated at high levels of LLO-containing
liposome excess, as determined by total cellular recovery
measurements, which may also have contributed to lower
transfection levels. It is important to note, however, that
all luciferase assay results were normalized for cellular
protein recovery, and thus any results strictly attributed
to lower cell numbers were corrected for.
Our data verify that pH-sensitivity is critical for
successful transfection using the LLO-LPDII complex. The
data in Figure 5 are consistent with the hypothesis that
LLO must be released from its liposomal encapsulation
in order to facilitate delivery of the condensed plasmid
pDNA from the endosome into the cytosol, similar to
the results for the delivery of other macromolecules
[11,17]. This data suggests that the transfection utilizing
LLO-LPDII is largely dependent on destabilization of the
liposomal carrier in the endosome, making pH-sensitive
liposomes a critical component of the LLO-LPDII system
through facilitating improved transfection in the LLO-
LPDII system, consistent with endosomal escape and
subsequent cytosolic delivery as the route of delivery.
Protamine-DNA alone, LPDII particles, and LLO-LPDII
complexes transfected cells similarly in the presence
and absence of 5% FBS (Figure 6), demonstrating
that these anionic LLO-LPDII particles are serum-
compatible. As serum is unavoidable in vivo, such
compatibility is important in gene delivery carrier
development. Furthermore, this result is in contrast with
cationic delivery vehicles which tend to decrease their
effectiveness in the presence of serum [4,26,27].
To gauge the efficacy of this modified LLO-LPDII system,
we compared the transfection levels of the complex in
the presence and absence of 5% serum with several
commonly used in vitro transfection agents: chloroquine,
DOTAP/DOPE cationic liposomes, and Lipofectamine
(Figure 7). In the presence of 5% FBS in the transfection
media, the LLO-LPDII particle showed transfection levels
comparable to both cationic lipid formulations and
chloroquine-mediated transfection. The ability of the LLO-
LPDII particle to maintain its transfection levels in the
presence of serum at a level that is comparable to these
common transfection agents shows its promise as a serum-
compatible delivery vehicle, though further enhancement
of this system through additional modifications such as
targeting may allow for even higher transfection levels.
Methods to overcome the series of barriers to DNA
delivery must continue to be developed. LLO-LPDII
has been shown here to enhance transfection levels
significantly over its anionic LPDII predecessor, and
additionally it maintains the ability to be targeted.
The combination of the two concepts, improved uptake
due to targeting and enhanced cytosolic delivery by
LLO incorporation, would effectively surpass two major
barriers to pDNA delivery at the level of the cell.
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Additionally, although not tested in this report, the use of
protamine sulfate may facilitate localization to the nucleus
through its NLS-like sequences [28]. As there is a potential
drug delivery loss at any barrier to delivery, systems which
combine different delivery methods are most likely to
ultimately enhance gene delivery to adequate levels for
vaccine delivery or gene therapy. This paper demonstrates
the successful combination of two technologies, the LPDII
anionic liposome system and LLO, an endosomolytic pore-
forming protein. Conceptualization and validation of the
LLO-LPDII hybrid system represents an important step
toward efficiently expanding the scope of gene delivery
applications.
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